SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-021271
Filing Date
2023-06-14
Accepted
2023-06-14 17:09:11
Documents
57
Period of Report
2023-04-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 766752
2 ex31-1.htm EX-31.1 19650
3 ex31-2.htm EX-31.2 20271
4 ex32-1.htm EX-32.1 8130
5 ex32-2.htm EX-32.2 8249
  Complete submission text file 0001493152-23-021271.txt   4085214

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE anix-20230430.xsd EX-101.SCH 27996
7 XBRL CALCULATION FILE anix-20230430_cal.xml EX-101.CAL 40148
8 XBRL DEFINITION FILE anix-20230430_def.xml EX-101.DEF 138168
9 XBRL LABEL FILE anix-20230430_lab.xml EX-101.LAB 255749
10 XBRL PRESENTATION FILE anix-20230430_pre.xml EX-101.PRE 202397
51 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 615072
Mailing Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118
Business Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118 408-708-9808
Anixa Biosciences Inc (Filer) CIK: 0000715446 (see all company filings)

IRS No.: 112622630 | State of Incorp.: DE | Fiscal Year End: 1031
Type: 10-Q | Act: 34 | File No.: 001-37492 | Film No.: 231014953
SIC: 2834 Pharmaceutical Preparations